30-Jan-2026
No headlines found.
OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital
Globe Newswire (Thu, 15-Jan 1:00 PM ET)
Business Wire (Thu, 15-Jan 8:30 AM ET)
OraSure Submits CT/NG Molecular Self-Test and Colli-Pee Urine Collection Device for FDA Review
Globe Newswire (Mon, 5-Jan 8:00 AM ET)
Globe Newswire (Wed, 17-Dec 1:23 PM ET)
Business Wire (Wed, 17-Dec 8:00 AM ET)
OraSure to Participate in Upcoming Investor Conference
Globe Newswire (Mon, 17-Nov 7:45 AM ET)
OraSure Announces Third Quarter 2025 Financial Results
Globe Newswire (Wed, 5-Nov 4:05 PM ET)
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
Orasure Technologies trades on the NASDAQ stock market under the symbol OSUR.
As of January 30, 2026, OSUR stock price was flat at $2.79 with 454,888 million shares trading.
OSUR has a beta of 0.69, meaning it tends to be less sensitive to market movements. OSUR has a correlation of 0.08 to the broad based SPY ETF.
OSUR has a market cap of $200.14 million. This is considered a Small Cap stock.
Last quarter Orasure Technologies reported $27 million in Revenue and -$.13 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.04.
In the last 3 years, OSUR traded as high as $8.45 and as low as $2.08.
The top ETF exchange traded funds that OSUR belongs to (by Net Assets): VTI, IWM, VXF, IWN, SCHA.
OSUR has underperformed the market in the last year with a return of -30.1%, while SPY returned +15.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in OSUR shares. However, OSUR has outperformed the market in the last 3 month and 2 week periods, returning +3.3% and +3.7%, while SPY returned +2.1% and 0.0%, respectively. This indicates OSUR has been having a stronger performance recently.
OSUR support price is $2.70 and resistance is $2.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OSUR shares will trade within this expected range on the day.